The Lancet Neurology in conversation with

The Lancet Group
The Lancet Group
  • 0,0 (0)
  • Médecine
  • Tous les mois

Explore the latest breakthroughs in brain health and neurological disease through interviews with leading researchers, neurologists, and policy experts. Each episode breaks down complex topics for a broad audience, translating cutting-edge science into practical insights. Editors at The Lancet Neurology, the world-leading clinical neurology journal, interview the investigators at the forefront of stroke, Alzheimer’s disease, epilepsy, migraine, Parkinson’s disease, multiple sclerosis, sleep disorders, traumatic brain injury, and other neurological challenges.

  1. 15 juil.

    Jan D Lünemann and Christian Münz on Epstein–Barr virus and multiple sclerosis

    In this episode, Heather Brown, Senior Editor at The Lancet Neurology, chats with Jan Lünemann (University of British Columbia, Canada) and Christian Münz (University of Zürich, Switzerland) about their Rapid Review on Epstein-Barr virus (EBV) and multiple sclerosis (MS). EBV, a common herpesvirus, has been strongly implicated in development of MS, and recent mechanistic advances are providing new insights into how EBV might cause MS in some people but not others. We also discuss the potential for prevention of MS with EBV vaccines, whether therapies targeting EBV might eventually be useful for MS treatment, and important unanswered questions and next steps for the field. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00177-8/fulltext

  2. 17 juin

    Hal Dietz discusses the role of genetics in spinal CSF leaks

    In this episode of In Conversation With, Morgane Boillot, Senior Editor at The Lancet Neurology, speaks with connective tissue disorders — including Marfan syndrome — and human genetics expert Hal Dietz from Johns Hopkins Medicine (Baltimore, USA) about the genetics of spontaneous spinal CSF leaks. Together, they explore the clinical presentation, diagnosis, and current treatment of spontaneous spinal CSF leaks, and discuss genetic findings revealing rare deleterious variants in FBN2, the gene encoding fibrillin-2, in patients with type 1b leaks. The conversation covers translational and mechanistic findings — including CRISPR-Cas9 mouse models and cellular interactions with the extracellular matrix — and what these reveal about the underlying biology of fibrillin-1 and fibrillin-2-related disorders. It also addresses the potential clinical implications of these findings, and Professor Dietz shares his hopes for their use in therapeutic development. Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00140-7/fulltext

  3. 16 juin

    Tony Schapira on GBA1 Parkinson's disease

    In this episode of In Conversation With, Elena Becker-Barroso, Editor-in-Chief of The Lancet Neurology, speaks with movement disorders specialist Tony Schapira from UCL’s Queen Square Institute of Neurology about GBA1-associated Parkinson’s disease. Together, they explore the genetic, clinical, and biochemical links between GBA1 variants, lysosomal function, Gaucher disease, alpha-synuclein pathology, and Parkinson’s progression. The conversation also highlights current challenges in risk prediction, biomarkers, genetic counselling, clinical management, and emerging therapeutic approaches aimed at modifying or even preventing disease. Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00090-6/fulltext

  4. 17 avr.

    Henry Brodaty and Alice Powell on cognitive resilience and ageing

    Join The Lancet Neurology’s In Conversation With… as editors Elena Becker-Barroso and Laura Hart welcome Henry Brodaty and Alice Powell from the University of New South Wales (Sydney, Australia) to discuss cognitive resilience and ageing. This episode teases apart cognitive resilience, cognitive reserve, brain maintenance, and brain reserve; explores how social determinants, life-course factors, and vascular health shape resilience; and delves into robust measures, biomarkers, and how pathologies interact with resilience. It also covers multicomponent interventions and their transferability to low-income and middle-income countries, how clinicians should communicate risk, and the key knowledge gaps and priorities for global cognitive resilience research. Don’t miss this timely exploration of dementia prevention and healthy brain ageing. Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00027-X/fulltext

  5. 18 mars

    Niklas Mattsson-Carlgren on the use of biomarkers in the diagnosis and stratification of Alzheimer’s disease

    In this episode, Laura Hart and Elena Becker-Barroso speak with Niklas Mattsson-Carlgren (Lund University) about the use of blood biomarkers in the diagnosis and stratification of Alzheimer's disease. They discuss two particular plasma biomarkers—p-tau217 and eMTBR-tau243—including what they measure and how a proposed practical two-step approach that uses p-tau217 as an initial screen in a neurology clinic, and then eMTBR-tau243 for those who test positive, could support diagnostic decisions.  Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00029-3/fulltext Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.  You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  6. 18 févr.

    Cristina Tassorelli on migraine prevention

    In this episode, Senior Editor Morgane Boillot speaks with Professor Cristina Tassorelli (University of Pavia, Italy) about recent advances in migraine prevention.  Together with colleagues, Tassorelli has authored a Review in the journal examining the major developments in migraine-specific pharmacological treatments over the past decade, with a particular focus on therapies targeting the CGRP pathway.  In this conversation, they explore what these advances mean for people living with migraine and for clinicians, discuss promising emerging targets for prevention and the future of biomarkers, and consider whether it is time to redefine the goals of migraine prevention with greater ambition.  Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00477-6/fulltext Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.  You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  7. 21 janv.

    Inga Zerr and Simon Mead on advances in prion diseases

    Our Editor-in-Chief, Elena Becker-Barroso, speaks with Inga Zerr (DZNE, Göttingen, Germany) and Simon Mead (UCL London, UK) about the latest advances in prion diseases.  In collaboration with other experts, Zerr and Mead have authored a Series in the journal that covers the genetic factors behind these diseases, and new diagnostic and prognostic biomarkers. Click here to read the full articles: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00451-X/fulltext https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00406-5/fulltext Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.  You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  8. 19/12/2025

    Julia Greenland on azathioprine for early Parkinson’s disease

    Host Morgane Boillot chats with Dr Julia Greenland about a clinical trial of azathioprine in early Parkinson's disease.  Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00386-2/fulltext Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.  You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Tout afficher (71)

À propos

Explore the latest breakthroughs in brain health and neurological disease through interviews with leading researchers, neurologists, and policy experts. Each episode breaks down complex topics for a broad audience, translating cutting-edge science into practical insights. Editors at The Lancet Neurology, the world-leading clinical neurology journal, interview the investigators at the forefront of stroke, Alzheimer’s disease, epilepsy, migraine, Parkinson’s disease, multiple sclerosis, sleep disorders, traumatic brain injury, and other neurological challenges.

Informations

Plus de contenus par The Lancet Group